Biofrontera AG is a biopharmaceutical company focused on developing and marketing dermatology drugs and medical skincare products, operating as a single business segment. Its key products include Ameluz, the BF-RhodoLED lamp, Belixos, and Xepi.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biofrontera's research and development (R&D) initiatives focus on the development of nanoemulsion and Ameluz, which are carried out by Biofrontera Bioscience GmbH. The company is responsible for pharmaceutical development, conducting preclinical and clinical studies, and granting, maintaining, and extending the drug approvals. The development of the new red-light lamp RhodoLED XL was undertaken by Biofrontera Pharma GmbH. All ongoing clinical studies are carried out in the US, as part of the agreement entered into with Biofrontera Inc to expand labeling for the US market. The company is also aiming for the US approval of Ameluz for superficial basal cell carcinoma, acne, as well as new indications for actinic keratosis for areas beyond the face and scalp. The company is advancing its pipeline candidates Ameluz for the treatment of moderate to severe acne in phase II; for the treatment of superficial basal cell carcinoma (sBCC), and for the treatment of actinic keratosis on the extremities, neck and trunk in a Phase III trial. In FY2024, the company spent EUR5.1 million on its R&D activities, which as a percentage of revenue stood at 23.8% and grew 32.6% YoY.